ART 6043
Alternative Names: ART-6043Latest Information Update: 26 Feb 2026
At a glance
- Originator Artios Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA polymerase theta inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 23 Feb 2026 ART 6043 receives Fast track status from the US FDA for HER2-Negative breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater (9461036)
- 17 Nov 2025 Artios Pharma plans a phase II trial for HER2-negative breast cancer (Metastatic disease) in November 2025
- 17 Oct 2025 Efficacy, adverse events, pharmacodynamics, drug interaction and pharmacokinetics data from a phase I/IIa trial in Solid tumours released by Artios Pharma